Table 4.
The relationship between the IGF and ER mRNA expression and clinico-pathological features of endometrioid adenocarcinoma
| Clinical pathology (n) | IGF-1 | IGF-2 | IGF-1R | IGF-2R | IGFBP-3 | ERα | ERβ | |
|---|---|---|---|---|---|---|---|---|
| Surgico-pathological stage |
I(33) |
1.70 ± 0.73▾ |
3.28 ± 2.17▾ |
1.62 ± 0.86 |
4.97 ± 2.77 |
14.91 ± 13.03 |
16.57 ± 4.1▾ |
42.04 ± 23.28 |
| II(15) |
0.58 ± 0.09* |
1.73 ± 2.47 |
1.84 ± 0.96 |
4.70 ± 2.96* |
13.25 ± 13.32 |
4.33 ± 2.39* |
25.70 ± 24.47* |
|
| |
III(10) |
0.44 ± 0.02# |
0.72 ± 1.31# |
1.50 ± 0.79 |
1.60 ± 2.50# |
14.83 ± 16.79 |
0.72 ± 0.33# |
5.07 ± 2.11# |
| Histological grade |
G1(14) |
1.44 ± 0.24 |
3.25 ± 2.27 |
1.53 ± 1.92 |
4.75 ± 3.01 |
16.22 ± 14.47 |
16.85 ± 4.37▴ |
41.93 ± 26.78 |
| G2(31) |
1.39 ± 0.95$ |
2.53 ± 2.38$ |
1.32 ± 0.99 |
4.92 ± 2.63$ |
11.78 ± 11.27 |
11.70 ± 6.94$ |
35.08 ± 23.96$ |
|
| |
G2(13) |
0.47 ± 0.07& |
1.34 ± 2.02& |
1.66 ± 0.84 |
2.42 ± 3.27& |
18.99 ± 16.87 |
1.55 ± 1.79& |
11.47 ± 16.42& |
| Depth of myometrial invasion |
≤ 50%(39) |
1.47 ± 0.79 |
3.14 ± 2.27 |
1.55 ± 0.90 |
5.26 ± 2.68 |
15.82 ± 12.78 |
14.28 ± 5.64 |
41.48 ± 24.10 |
| >50%(19) | 0.63 ± 0.46@ | 0.98 ± 1.76@ | 1.15 ± 0.78 | 2.39 ± 2.75@ | 11.69 ± 15.01 | 3.26 ± 5.86@ | 10.83 ± 12.55@ | |
▾p < 0.05 stage I vs stage II;*P < 0.05 stage II vs stage III; #P < 0.05 stage I vs stage III;▴P < 0.05 G1 vs G2;$P < 0.05 G2 vs G3;&P < 0.05 G1 vs G3;@P < 0.05 vs ≤50% of mymetrial invasion by one-way ANOVA.